Abstract: An automated cardiopulmonary resuscitation (ACPR) device includes a compression element for acting on a compression location on a chest of a patient, and an optical alignment aid configured and arranged for projecting, at least temporarily, a light pattern on the patient's chest. The light pattern projected by the optical alignment aid guides the user during the placement procedure of the ACPR device. The light pattern projected by the optical alignment aid allows the user to monitor whether the position of the automated cardiopulmonary resuscitation device has moved during the administration of CPR.

Abstract: A method for performing cardiopulmonary resuscitation (CPR) includes elevating the heart of an individual to a first height relative to a lower body of the individual. The lower body may be in a substantially horizontal plane. The method may also include elevating the head of the individual to a second height relative to the lower body of the individual. The second height may be greater than the first height. The method may further include performing one or more of a type of CPR or a type of intrathoracic pressure regulation while elevating the heart and the head. The first height and the second height may be determined based on one or both of the type of CPR or the type of intrathoracic pressure regulation.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine).

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LUCENTIS® (ranibizumab), BEXSERO® (meningococcal group B vaccine [rDNA, component, adsorbed]), AIN457 (secukinumab) or RELAXIN® (serelaxin).

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LYXUMIA (lixisenatide), LEMTRADA (alemtuzumab), REGN727/SAR236553 (alirocumab), SAR2405550/BSI-201 (iniparib), OTAMIXABAN (otamixaban), SARILUMAB (sarilumab), LANTUS and LYXUMIA (insulin glargine and lixisenatide) or VISAMERIN/MULSEVO (semuloparin sodium).

Abstract: People can damage their medicines by taking them outside in hot or cold weather. On the other hand, some people need to carry their medicines with them wherever they go (even if the weather is extremely hot or cold). Specially constructed storage systems can protect medicines from damage due to hot and cold weather without requiring bulky structures or expensive components that consume electricity to regulate temperature.

Abstract: A multi-medicament container including a vessel body, a plurality of plungers, and a rod is disclosed. The vessel body has an opening end and a closed end. The plungers are received in the vessel body, with the plungers spaced from each other to define a plurality of chambers in the vessel body, with each of the plungers having a passage, and with the passages having a common central line. The rod detachably and fluid-tightly stuffs the passages of the plungers, with an end of the rod extending out of the vessel body from the opening end of the vessel body.

Abstract: A modular pacifier assembly having a modular mouth guard assembly including a nipple. The modular mouth guard assembly includes a mouth guard shield and a removable mouth guard plate that interconnects into the mouth guard shield.

Abstract: Three adhesives formulated with Trimethylolpropane Trimethacrylate (TMPTMA) that do not contain BisGMA were developed, whereby the mutagenic and teratogenic risk by the release of bisphenol A is eliminated, and presented a better performance compared to the three commercial adhesives prepared with BisGMA (Adhesive A, Adhesive C and Adhesive B). The invention provides an adhesive used in one-step and provides a system which is formed by a primer and a slurry. The adhesives of the invention were compared with two commercial controls. They were physically characterized by assessing: hardening time, adhesion stress, elastic modulus, sorption and solubility at different pHs (6.8 and 7.7); by the obtained values premature detachments, white lesions below the appliance and microfiltration are avoided; its fluidity, film thickness were evaluated and were compared with those obtained from the three commercial adhesives. Storage stability and thermogravimetric analysis were assessed.

Abstract: The present invention relates to a cosmetic composition based on a magnetic or magnetizable material, the preparation thereof and use thereof for surface and deep cleansing of the epidermis. Said cosmetic composition has revealed to be particularly useful for preparing a mask for cleansing the epidermis of the face, breast, hands and body and, simultaneously, for maintaining the aesthetic appearance and functional efficiency thereof.

Abstract: A color-changing composition for caring for and/or making up keratin materials is disclosed. The composition comprises: —a physiologically acceptable medium including at least an aqueous phase, —color-changing microcapsules, said microcapsules having a size ranging from 50 ?m to 1000 ?m, preferably from 80 ?m to 800 ?m, in particular from 100 ?m to 400 ?m, and comprising: (A) a core, having preferably a size ranging from 20 ?m to 800 ?m, comprising at least one colorant and preferably at least one binder, said colorant(s) including preferably at least one inorganic pigment preferably selected from iron oxide(s), and (B) a pressure-breakable wall layer surrounding said core, having preferably a thickness of 10 ?m to 300 ?m, comprising at least one colorant and preferably at least one binder, said colorant(s) including preferably at least titanium dioxide particles, Wherein said microcapsules includes at least 70% by weight of colorant(s), compared to the total weight of said microcapsules.

Abstract: Animate surface treatment compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a metal ion source material which releases copper ions and/or zinc ions into the treatment composition, in certain embodiments at least one alcohol which independently of other constituents present exhibits a microbicidal effect, in certain embodiments at least one quaternary ammonium compound which provides a microbicidal benefit, optionally but very preferably also at least one detersive surfactant, further optionally one or more further constituents which impart one or more advantageous technical or aesthetic benefits to the compositions, including one or more detersive surfactants, and water, wherein the compositions are at a pH such that the animate surface treatment compositions, exhibit a microbicidal or germicidal or antimicrobial effect on treated surfaces, which compositions are characterized in exhibiting a microbicidal benefit when tested against one or more challeng

Abstract: An agent for dyeing and/or bleaching keratin fibers, in particular human hair, including in a cosmetic carrier (a) at least one fatty alcohol selected from the group of arachyl alcohol (eicosan-1-ol), gadoleyl alcohol ((9Z)-eicos-9-en-1-ol), arachidonic alcohol ((5Z,8Z,11Z,14Z)-eicosa-5,8,11,14-tetraen-1-ol), heneicosyl alcohol (heneicosan-1-ol), behenyl alcohol (docosan-1-ol), erucyl alcohol ((13Z)-docos-13-en-1-ol) and brassidyl alcohol ((13E)-docosen-1-ol), (b) at least one persulfate salt selected from the group of ammonium persulfate, potassium persulfate and sodium persulfate, and (c) at least one glyceryl fatty acid ester of general formula (I), in which R1, R2 and R3 independently of one another stand for a hydrogen atom or a grouping of formula (II), in which R4 stands for an unbranched or branched, saturated or unsaturated C11-C28 alkyl group, with the proviso that at least one and at most two of the radicals selected from R1, R2 and R3 stand for a grouping of formula (II).

Abstract: Provided is a powder hair dye composition capable of, in a hair-dyeing treatment intended to give a sharp black hue, suppressing the development of redness without being affected by the leave-on time required for the hair-dyeing treatment, while ensuring a sufficient hair-dyeing power. The powder hair dye composition contains (A) sodium percarbonate whose content is 1.8 to 3.7 mass % at the time of use, (B) p-phenylenediamine sulfate, and (C) m-aminophenol sulfate.

Abstract: Provided are methods of screening antioxidants for skin protective capacity and antioxidant formulations which protect the skin from UV radiation. The method of screening antioxidants for protecting the skin from UV radiation includes using the Briggs-Rauscher Oxidant Method (BROM) method to one or more antioxidants for predicting protection to the epidermal layer. One advantageous antioxidant formulation for use in sun screens, lip balms and other types of topically applied skin care products for protecting the skin from UV radiation includes a mixture of antioxidants in the skin care product including an effective amount of arbutin in combination with BHT, wherein the ratio of arbutin to BHT in the skin care product ranges from 1:4 to 4:1, and wherein the measured BROM value of the antioxidant mixture is greater than the sum of the BROM values of the individual antioxidants in the mixture at the same concentration. The measured BROM value of the resultant product is greater than or equal to 0.2 sec/?g.

Abstract: An agent for oxidatively dyeing keratin fibers includes in a cosmetic carrier, (A) as developer, 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof, (B) as developer, at least one pyrimidine derivative selected from 2,4,5,6-tetraaminopyrimidine, 4-hydroxy-2,5,6-triaminopyrimidine, 2-hydroxy-4,5,6-triaminopyrimidine and/or one of the physiologically acceptable salts thereof, (C) as coupler, at least one m-diaminobenzene derivative selected from 2-(2,4 -diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene, 2,6-bis(2?-hydroxyethylamino)-1-methylbenzene, and/or one of the physiologically acceptable salts thereof, and (D) as coupler, at least one m-aminophenol derivative selected from 3-aminophenol, 5-amino-2-methylphenol and/or one of the physiologically acceptable salts thereof.

Abstract: An agent for oxidatively dyeing keratinous fibers includes in a cosmetic carrier: (A) 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof as developer; (B) at least one p-aminophenol derivative from the group comprising p-aminophenol, 4-amino-3-methylphenol, and/or the physiologically acceptable salts thereof as developer; (C) at least one m-diaminobenzene derivative from the group comprising 2-(2,4-diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene, 2,6-bis(2?-hydroxyethylamino)-1-methylbenzene, and/or one of the physiologically compatible salts thereof as coupler; and (D) at least one m-aminophenol derivative from the group 3-aminophenol, 5-amino-2-methylphenol and/or one of the physiologically acceptable salts thereof as coupler, wherein the molar ratio of all the developers of group (A) included in the agent to all the developers of group (B) included in the agent, i.e., the molar ratio (A)/(B), has a value of at least 1.2.

Abstract: An agent for oxidatively dyeing of keratinic fibers includes, in a cosmetic carrier, (A) 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof as developer, (B) at least one pyrimidine derivative selected from 2,4,5,6-tetraaminopyrimidin, 4-hydroxy-2,5,6-triaminopyrimidin, 2-hydroxy-4,5,6-triaminopyrimidin and/or one of the physiologically acceptable salts thereof as developer, (C) at least one m-diaminobenzene derivative selected from 2-(2,4-diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene, 2,6-bis(2?-hydroxy-ethylamino)-1-methylbenzene, and/or one of the physiologically acceptable salts thereof as coupler, and (D) at least one m-dihydroxybenzoyl derivative selected from resorcinol, 2-methylresorcinol and/or 4-chlororesorcinol as coupler.

Abstract: A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.

Abstract: The present invention provides a water-based skin cosmetic comprising the following ingredients (A) and (B): (A) A compound represented by the following formula (I) (In this formula, l and m can be either the same or different; each denotes an integer 10-25.) (B) A thickener composed of microgel obtained by using a composition that has an organic solvent or oil component as the dispersion medium and water as the dispersion phase, dissolving a water soluble ethylenically unsaturated monomer in the dispersion phase, and radically polymerizing it in the dispersion phase, wherein said microgel is obtained by radically polymerizing dimethylacrylamide and 2-acrylamido-2 methylpropane sulfonic acid under the conditions in which a single phase microemulsion or fine W/O emulsion is formed by using a surfactant.

Abstract: An antiperspirant/deodorant liquid composition comprising a solvent, an antiperspirant and/or deodorant ingredient, a fragrance, and an alkylated polyvinylpyrrolidone, wherein the alkylated polyvinylpyrrolidone is soluble or dispersible in the composition. The alkylated polyvinylpyrrolidone is capable of forming a film when the solvent is allowed to evaporate such that the film limits the release of the fragrance. Fragrance is released when the film is exposed to perspiration. The alkylated polyvinylpyrrolidone overcomes the problem with other film forming polymers that do not form stable films in the presence of an antiperspirant and/or deodorant ingredient.

Abstract: Device and method for treating hyperhidrosis, neuropathy, skin, circulation, muscle stimulation, by application of a fabric including an elemental zinc particle deposition to a treatment area of the skin.

Abstract: The present invention is directed to the provision of a pharmaceutical suspension. The suspension includes high molecular weight polyethylene glycol as a suspending agent. The suspension also typically includes an antimicrobial agent (e.g., polymeric quaternary ammonium compound), an antimicrobial system (e.g., borate/polyol complex system) or both. The suspension has been found particularly useful as an ophthalmic suspension, but can be used in other instances as well.

Abstract: An aqueous ophthalmic solution containing a relatively high concentration of olopatadine in solubilized form is provided. The solution comprises a combination of at least two non-ionic surfactants and is essentially devoid of cyclodextrins. The solution is useful for providing enhanced relief from symptoms of ocular allergic disorders (e.g. conjunctivitis).

Abstract: The present invention provides a chewing gum composition comprising a gum base matrix and a bulk portion, wherein the chewing gum composition comprises nicotine and includes a cross-linked polyacrylic acid, such as a carbomer, added in an amount of 0.1 to 5.0% by weight of the chewing gum composition. The invention may be used to enhance the release of nicotine in a nicotine chewing gum.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.

Abstract: Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.

Abstract: A pharmaceutical composition comprising an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2?-(1H-tetrazol-5-yl)[1,1?-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid characterized in that when exposed to 75% relative humidity at 40° in open dish for one month the total amount of related substances does not increase more than 1% is described.

Abstract: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.

Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.

Abstract: A one-step method for fabricating solidified particles from all-aqueous emulsion droplets involves solidification and drying of the droplets by osmosis. According to this method the fabrication of solidified particles is induced by implementing a high osmotic pressure gradient between the internal phase and external phase of the all-aqueous emulsion. The resultant extraction of water leads to solidification of the emulsion droplets. This approach provides mild conditions for encapsulating bioactive ingredients or other delicate components to conveniently fabricate bio- and cyto-compatible particles because it does not involve the introduction of external energy used in conventional drying. Such conventional external energy inputs are time-consuming, so the method is more efficient.

Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent liquid filled capsule containing polyethylene glycol and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is abuse deterrent to parenteral administration. The present disclosure also relates to processes of preparing the dosage form.

Abstract: Nanoparticles with entrapped, nonpolar compounds are disclosed, and a method for their synthesis. The nanoparticles are readily dissolved or dispersed in water. For example, the entrapped nonpolar compounds may include pharmaceutically-active compounds, or natural colorants. The nanoparticles have a nonpolar compound core, an intermediate surfactant layer, and an outer crosslinked polymeric protective layer. In a prototype example, alginic acid nanoparticles were prepared with beta-carotene entrapped in the core, with lecithin as the intermediate surfactant layer. In an alternative embodiment, a layer-by-layer assembly technique may be used to entrap the colorant within nanoparticles.

Abstract: A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, the formulation comprising protein-protein core-shell particle configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enable treatment against the diseases such as cancer, inflammatory and auto-immune diseases.

Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of a drug, particularly, a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms and a polyvalent alcohol having 3-8 carbon atoms. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms, a polyvalent alcohol having 3-8 carbon atoms and an organic amine having 2-9 carbon atoms.

Abstract: A transdermal preparation comprising a multivalent metal chloride, a basic drug having an amino group, and an ester group-containing base material, is useful because of its excellent drug content stability.

Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of an acidic drug, comprising a polyvalent alcohol having 3-8 carbon atoms, a higher alcohol having 12-20 carbon atoms and an organic amine having 2-9 carbon atoms.

Abstract: The present invention relates to an injectable pharmaceutical formulation for the alleviation or reduction of joint irritation or for the reduction of worsening of existing joint inflammation, formulated for intra-articular injection comprising an active polyol ingredient, which polyol active ingredient is xylitol. Use of an intra-articular injectable formulations for the treatment of joint diseases or conditions including arthritis is described.

Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of cerebral hemorrhage and subarachnoid hemorrhage. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, cerebral hemorrhage and subarachnoid hemorrhage. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the cerebral hemorrhage and subarachnoid hemorrhage.

Abstract: The invention provides a gel patch comprising a support and an adhesive layer on the support, wherein the adhesive layer comprises 1.5 to 2.5 mass % of ketoprofen, 1.5 to 2.5 mass % of 4-tert-butyl-4?-methoxydibenzoylmethane and 12 to 18 mass % of propylene glycol, based on the total mass of the adhesive layer.

Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I): R1—NHCH2COCH2CH2COOR2??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.

Abstract: The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.

Abstract: Composition for use in the treatment of stroke, particularly in patients with dysphagia, the composition comprising an active agent, said active agent comprising the amino acids leucine, isoleucine, valine, lysine, threonine and at least one of histidine, phenylalanine, methionine, tryptophan, tyrosine, cystine. The composition further comprises one or more thickener agents in an amount between 10% and 50% by weight, more preferably between 20% and 30% by weight, with respect to the active agent weight.

Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

Abstract: The present invention provides a metabolism improving agent comprising an oxo fatty acid having 18 carbon atoms and a carbonyl group at the 10- or 12-position, and/or a hydroxy fatty acid having 18 carbon atoms and a hydroxyl group at the 10- and/or 12-position(s), and use of the metabolism improving agent as a food, a pharmaceutical product and the like.